The Swiss pharmaceutical giant Novartis has officially agreed to acquire UK-based biotechnology firm Myricx Bio. The Novartis Myricx Bio acquisition is valued at up to $1.5 billion, which includes a substantial $1.1 billion upfront cash payment and up to $400 million in potential milestone achievements. Through this strategic move, the company is sharply focusing on strengthening the Novartis ADC pipeline. By integrating next-generation antibody-drug conjugates (ADCs) into its research engine, Novartis aims to overcome the limitations of current oncology therapies and deliver highly targeted, durable treatments for cancer patients worldwide.
Novartis to Acquire Myricx Bio To Expand Oncology Treatment
The Novartis acquisition of Myricx Bio represents a major financial and scientific commitment to advanced precision medicine. Under the official terms of the Novartis Myricx Bio acquisition, the financial structure guarantees $1.1 billion in upfront liquidity to Myricx Bio, with the remaining $400 million tied to rigorous clinical and regulatory milestones.
The Novartis Myricx Bio deal is currently slated to close in the second half of 2026, pending customary closing conditions and necessary regulatory approvals.
The core purpose of the Myricx Bio acquisition by Novartis is the seamless integration of Myricx Bio’s proprietary ADC technology directly into Novartis’ global research portfolio. This transaction aligns perfectly with Novartis’ long-term oncology strategy to scale innovative, platform-based therapies that target cancer cells with pinpoint accuracy.
Rather than relying solely on internal discovery, the Myricx Bio acquisition allows the pharma giant Novartis to purchase a validated, sophisticated drug-delivery platform.
What is Myricx Bio’s ADC Platform?
Antibody-drug conjugates, or ADCs by Myricx Bio, are highly targeted cancer medicines often described as “guided missiles.” They consist of a monoclonal antibody bound to a therapeutic drug payload, designed to seek out specific proteins on tumor cells and destroy them while sparing healthy tissue.
While traditional ADCs utilize topoisomerase I (TOPO-1) or microtubule inhibitors, Myricx Bio has pioneered a first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. NMT is a vital enzyme that cancer cells rely heavily upon to grow and survive. By deploying an NMTi payload, this platform disrupts critical internal cellular processes, offering distinct advantages over existing treatments.
Most notably, preclinical testing indicates that these novel payloads can successfully overcome the therapy resistance commonly associated with older TOPO-1 inhibitor-based ADCs, opening up massive possibilities for treating diverse solid tumors.
As Fiona Marshall, President of Biomedical Research at Novartis, noted, “ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients.”
Myricx Bio’s Lead Cancer Programs Joining the Novartis Pipeline
Following the Novartis Myricx Bio acquisition, Novartis will absorb two highly promising lead ADC candidates currently undergoing advanced preclinical development:
- B7-H3-Targeted ADC: Designed to combat solid tumors expressing the B7-H3 protein, entering a competitive but clinically validated arena of oncology.
- HER2-Targeted ADC: Aimed at tumors expressing HER2, built to challenge or complement existing blockbuster treatments by effectively targeting TOPO-1-resistant models.
These assets possess broad potential applications across a wide variety of difficult-to-treat solid tumor indications. Securing these ADC candidates from Myricx Bio gives Novartis an immediate opportunity to broaden its targeted oncology footprint with therapies in the pharmaceutical industry.
Myricx Bio’s Industry Exit With Novartis Deal
Myricx Bio boasts an impressive pedigree, having originally spun out from world-class UK institutions, including Imperial College London and the Francis Crick Institute, with early support from Cancer Research UK. The company thrived under early backing from prominent venture capital firms, notably co-led by Sofinnova Partners, who helped guide the biotech’s pivotal shift from small-molecule development to a specialized ADC platform.
Myricx Bio’s final multi-billion-dollar exit reflects intense global industry interest in highly differentiated ADC technologies. As pharmaceutical companies rush to secure the next wave of oncology breakthroughs, this transaction underscores a robust era of biotech mergers and acquisitions focused on specialized, resistance-fighting cancer platforms.
Conclusion
The Novartis Myricx Bio acquisition marks a transformative moment in next-generation cancer drug development. By securing a $1.5 billion deal for Myricx’s novel NMTi ADC platform, Novartis is positioned to address critical gaps left by conventional chemotherapy and existing ADC designs.
If these preclinical assets achieve successful clinical validation in the coming years, this strategic integration could fundamentally reshape targeted oncology treatments and offer powerful new lifelines to cancer patients worldwide.
